The North America hereditary cancer testing market is expected to reach US$ 3,247.37 Mn in 2027 from US$ 1,255.79 Mn in 2018. The market is estimated to grow with a CAGR of 11.6% from 2019-2027.
The growth of the market is driven by factors such as, growing awareness about hereditary cancer and favorable reimbursement scenario. However, market growth is likely to slow down due to the gender gap in cancer genetic testing in the region.
Personalized medicines is a comparatively new idea that allows doctors to select medication based on a patient's hereditary profile; it is a developing area in the healthcare sector. The method not only reduces adverse side effects but also manages to produce strong results in a short period. For instance, mutations in BRCA1 and BRCA2 lead to breast cancer. However, identifying the type of variation in the breast cancer patient provides crucial information for the kind of treatment. Hence, personalized medicines allow right treatment at the right time, which reduces the mortality rate. On the back of these advantages, the personalized medicine approach is likely to create many opportunities for the hereditary cancer testing market players.
The US is expected to lead the market in the North America region to the rapidly increasing expenditure of research and development by biopharmaceutical companies. Moreover, various biopharmaceutical companies are focusing on the development of new cancer panel and direct to consumer test. Therefore, considering the factors mentioned above, growth of the market in the US is likely to contribute the most significant share in the North America region during the forecast period.
Exhibit: Mexico Hereditary cancer testing Market Revenue and Forecasts to 2027 (US$ Mn)
NORTH AMERICA HEREDITARY CANCER TESTING – MARKET SEGMENTATION
BY DIAGNOSIS TYPE
BY TECHNOLOGY
BY END USER
Company Profiles
| Report Attribute | Details |
|---|---|
| Market size in 2018 | US$ 1,255.79 Million |
| Market Size by 2027 | US$ 3,247.37 Million |
| CAGR (2019 - 2027) | 11.6% |
| Historical Data | 2016-2017 |
| Forecast period | 2019-2027 |
| Segments Covered |
By Diagnosis Type
|
| Regions and Countries Covered |
North America
|
| Market leaders and key company profiles |
|
The North America Hereditary Cancer Testing Market is valued at US$ 1,255.79 Million in 2018, it is projected to reach US$ 3,247.37 Million by 2027.
As per our report North America Hereditary Cancer Testing Market, the market size is valued at US$ 1,255.79 Million in 2018, projecting it to reach US$ 3,247.37 Million by 2027. This translates to a CAGR of approximately 11.6% during the forecast period.
The North America Hereditary Cancer Testing Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Hereditary Cancer Testing Market report:
The North America Hereditary Cancer Testing Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Hereditary Cancer Testing Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Hereditary Cancer Testing Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Hereditary Cancer Testing Market
